CLR01 protein found in semen increases the spread of Ebola virus infection
Penn study suggests that targeting amyloid fibrils could prevent sexual transmission...
List view / Grid view
Penn study suggests that targeting amyloid fibrils could prevent sexual transmission...
A new study presents an epigenetic drug capable of slowing down cell growth in Mantle Cell Lymphoma (MCL)...
For lead optimisation, target-based assays are still the most affordable means of rapidly performing fast iterations and remain core to screening. However, the desire for biological relevance is driving ongoing growth in cell-based assays.
There are no short-cuts in the complex field of lipidomics, explains Cristina Legido-Quigley, a Principal Investigator in Systems Medicine at Steno Diabetes Center Copenhagen in Denmark and at King’s College London.
This application note discusses how the Alpha SureFire® Ultra™ Multiplex technology provides a phosphoprotein multiplexing detection platform that is truly homogeneous and high throughput.
Declining R&D productivity is a key challenge in the pharmaceutical industry. To increase the success rate of candidate drugs entering the clinical phase, companies must address the early stages of drug discovery.
Predictiveness is one of the key factors for success in the drug discovery workflow. Many compounds fail at late stages due to lack of predictive data or the discovery of unwanted side effects.
Study of Drosophila links ceramide accumulation to heart dysfunction...
Researchers discover molecular nets inside heart muscles which hold promise for new heart failure treatment...
SMi Reports: SMi’s 2nd annual Drug Discovery conference, taking place in London on 21 and 22 March 2018, will discuss the role of artificial intelligence in drug discovery.
1 February 2018 | By PerkinElmer
This webinar discussed a screening assay that recapitulates the activation of ER stress sensor IRE1 and an assay to quantify cell migration phenotypes, as applied to cardiovascular target validation and drug discovery.
15 January 2018 | By BMG Labtech GmbH
Optimising the receptor binding kinetics of new drugs can have significant benefits, ranging from improved duration of action to enhanced efficacy through the insurmountable antagonism of dynamic physiological systems.Despite this, the kinetics of new receptor ligands are rarely measured early in the drug discovery process, largely because current assays are…
4 January 2018 | By IntelliCyt Corporation
In this webinar, speakers discussed how the IntelliCyt iQue Screener Plus platform is being utilised to deliver rich datasets for compound screening, target validation and is how it is transforming immuno-oncology.
In this scientific poster, PerkinElmer demonstrates the ease and utility of using AlphaLISA® and LANCE® TR-FRET homogenous assay forms for studying PPIs.